Flossbach Von Storch SE Buys Shares of 1,475,371 Stryker Corporation $SYK

Flossbach Von Storch SE purchased a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, Holdings Channel.com reports. The firm purchased 1,475,371 shares of the medical technology company’s stock, valued at approximately $464,506,000. Stryker comprises 2.1% of Flossbach Von Storch SE’s portfolio, making the stock its 17th biggest position.

A number of other hedge funds have also recently made changes to their positions in SYK. Gables Capital Management Inc. bought a new stake in Stryker during the second quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter worth about $26,000. Sankala Group LLC purchased a new stake in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the third quarter valued at about $27,000. Finally, Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $27,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SYK shares. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Piper Sandler cut their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Wells Fargo & Company lowered their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Sanford C. Bernstein set a $410.00 price target on Stryker in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Buying and Selling

In other Stryker news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 315,370 shares of company stock valued at $98,463,501 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Up 2.7%

NYSE:SYK opened at $340.20 on Thursday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $326.19 and a 200-day simple moving average of $332.95. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a market capitalization of $130.49 billion, a P/E ratio of 35.25, a PEG ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.